Company Overview and News
Jun 13, 2018 (LBO) – Fitch Ratings has affirmed the National Long-Term Rating of Sampath Bank at A+(lka) and revised the outlook to stable from negative.
Sampath Bank recommitted itself to offering technology driven, world class financial services to Sri Lankan consumers and businesses at an awe-inspiring event titled “Towards Vision 2020 with Sampath Stars” held at the Hilton Colombo, recently.
From left: Softlogic Holdings PLC Corporate Finance and Treasury Head Hiran Perera, HNB PLC Deputy General Manager Corporate Banking Ruwan Manatunga, Softlogic Holdings PLC Chairman and Managing Director Ashok Pathirage, Sampath Bank PLC Senior Deputy General Manager Corporate Banking Shashi Jassim and Bank of Ceylon PLC Deputy General Manager Corporate Banking and Offshore Banking Russel Fonseka
The Sri Lankan banks satisfy many of the key matrices such as growth, profits, efficiency and asset quality against most regional peers but the sector is in deep thirst for fresh capital as the banks brace for full implementation of BASEL III as early as in few months.
55BC CBQS HNB SAMP
Apr 02, 2018 (LBO) – Sri Lanka’s Department of Post with Sampath Bank unveiled e-Pay Mobile Cash, a service that leverages the wide spread network of post offices, sub-post offices and Sampath Bank ATMs around the island to enable real time money transfers in a secure and convenient manner.
Mar 26, 2018 (LBO) – Sampath Bank PLC has entered into a Memorandum of Understanding (MoU) with Ustocktrade LK (Private) Ltd (ULPL) to enable investors pay conveniently when trading in securities listed on stock exchanges across the United States of America (USA) through the Ustocktrade app.
From left: Finlays Colombo Limited Director Naresh Ratwatte, Finlays Colombo Limited Chairman and Managing Director Hunter Crawford, John Keells Holdings PLC Property Group President Suresh Rajendra and John Keells Holdings PLC Property Group Sector Head Nayana Mawilmada at the signing of the joint venture agreement
JFIN JKL SAMP
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to CSE:SAMP / SAMPATH BANK PLC on message board site Silicon Investor.
|San Marco (SMN.V) Samples 8.46 g/t Gold; 43.0 g/t Silver; 1.||Sampo-ryhm��n kokous|
|JNN-VSE HIT BIG ........21 oz. gold in grab samples|